AnaptysBio (ANAB) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings or view top-rated stocks.

5 analysts have issued 12 month price targets for AnaptysBio's shares. Their ANAB share price forecasts range from $26.00 to $45.00. On average, they predict the company's stock price to reach $34.75 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts.

AnaptysBio's stock was trading at $30.99 on January 1st, 2023. Since then, ANAB shares have decreased by 41.9% and is now trading at $18.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ANAB earnings forecast.

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.50) EPS for the quarter, beating analysts' consensus estimates of ($1.65) by $0.15. The biotechnology company earned $3.46 million during the quarter, compared to analysts' expectations of $5.50 million. AnaptysBio had a negative trailing twelve-month return on equity of 65.52% and a negative net margin of 1,113.38%.

Virtus LifeSci Biotech Clinical Trials ETF holds 5,859 shares of ANAB stock, representing 1.01% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.87%), Point72 Asset Management L.P. (5.50%), State Street Corp (4.57%), Braidwell LP (4.35%), Woodline Partners LP (3.90%) and Dimensional Fund Advisors LP (3.42%). Insiders that own company stock include Ecor1 Capital, Llc, Eric J Loumeau, Hamza Suria and Paul F Lizzul.
View institutional ownership trends.

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANAB stock can currently be purchased for approximately $18.00.

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $477.90 million and generates $10.29 million in revenue each year. The biotechnology company earns $-128,720,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.